There are currently 89 clinical trials in Wilmington, North Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including PMG Research of Wilmington, LLC, GSK Investigational Site, PMG Research of Wilmington and New Hanover Regional Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
SUNOSI® (Solriamfetol) Pregnancy Registry
NCT06413420
Recruiting
The SUNOSI (solriamfetol) Pregnancy Registry is a prospective, multi-country, observational study to evaluate the safety of solriamfetol exposure during pregnancy in women with a diagnosis of narcolepsy or obstructive sleep apnea (OSA).
Gender:
FEMALE
Ages:
All
Trial Updated:
05/09/2024
Locations: PPD, Inc., Wilmington, North Carolina
Conditions: Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring
Register for Updates
A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding
NCT05579548
Recruiting
This is a Phase 4 observational study designed to assess the impact of Palynziq ® (pegvaliase) treatment in pregnant women with PKU and on their offspring who were exposed to pegvaliase at any time during pregnancy and breastfeeding.
Gender:
FEMALE
Ages:
All
Trial Updated:
05/01/2024
Locations: Syneos Health, Wilmington, North Carolina
Conditions: Phenylketonuria, Maternal
Register for Updates
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
NCT04846959
Recruiting
The objective of this registry is to compare outcomes of risankizumab-exposed pregnancies with those of pregnancies that were not exposed to risankizumab among women with plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease (CD), or other conditions for which risankizumab is an FDA-approved treatment. The registry is designed to estimate the association between risankizumab and maternal, fetal, and infant outcomes by comparing the prevalence rates of these outcomes in the exposed and une... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
03/05/2024
Locations: PPD Development, LP /ID# 232134, Wilmington, North Carolina
Conditions: Plaque Psoriasis, Psoriatic Arthritis, Crohn Disease, Other Conditions for Which Risankizumab is an FDA-approved Treatment
Register for Updates
Mavacamten Pregnancy Surveillance Program
NCT05939700
Recruiting
The purpose of this observational pregnancy safety study is to assess maternal, fetal, and infant outcomes after exposure to mavacamten at any time during pregnancy and/or breastfeeding.
Gender:
FEMALE
Ages:
15 years and above
Trial Updated:
11/22/2023
Locations: The Mavacamten Pregnancy Surveillance Program, PPD Inc, Wilmington, North Carolina
Conditions: Breastfeeding, Hypertrophic Cardiomyopathy, Pregnancy Related
Register for Updates
Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects
NCT01137981
Recruiting
The APR began as the 'Zidovudine in pregnancy Registry' in January 1989 and became the 'Antiretroviral Pregnancy Registry' in January, 1993. The purpose of the APR is to detect any major teratogenic effects involving any of the Registry drugs when administered to pregnant HIV positive women. The Registry is intended to provide an early signal of teratogenicity associated with prenatal use of the antiretroviral drugs. The Registry collects data on prenatal exposures to antiretroviral drugs, poten... Read More
Gender:
Female
Ages:
All
Trial Updated:
10/04/2021
Locations: GSK Investigational Site, Wilmington, North Carolina
Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Register for Updates